OncoMatch/Clinical Trials/NCT04522544
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Is NCT04522544 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Tremelimumab and Durvalumab for hepatocellular carcinoma non-resectable.
Treatment: Tremelimumab · Durvalumab — A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with Y-90 SIRT for intermediate stage HCC
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer therapy
No prior systemic anti-cancer therapy
Cannot have received: radiotherapy
Exception: administered < 4 weeks prior to study entry
radiotherapy administered < 4 weeks prior to study entry
Cannot have received: endocrine therapy
endocrine- or immunotherapy or use of other investigational agents
Cannot have received: immunotherapy
endocrine- or immunotherapy or use of other investigational agents
Cannot have received: investigational agent
Exception: used within 4 weeks prior to the first dose of study treatment
has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
Cannot have received: locoregional therapy
Exception: ongoing or completed < 4 weeks prior to the baseline scan
Locoregional therapies ongoing or completed < 4 weeks prior to the baseline scan
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL, ANC ≥1.5 (or 1.0) x (> 1500 per mm^3), platelets ≥100 (or 75) x 10^9/L (>75,000 per mm^3)
Kidney function
Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine clearance CL>40 mL/min by Cockcroft-Gault formula or by 24-hour urine collection
Liver function
Child-Pugh A; Serum bilirubin ≤1.5 x institutional ULN; AST (SGOT), ALT (SGPT) ≤ 2.5 x institutional ULN unless liver metastases are present, in which case ≤5x ULN; INR ≤ 1.25; Albumin ≥ 31 g/dL
Adequate blood count, liver-enzymes, and renal function: Hemoglobin ≥ 9.0 g/dL, ANC ≥1.5 (or 1.0) x (> 1500 per mm^3), platelets ≥100 (or 75) x 10^9/L (>75,000 per mm^3); Serum bilirubin ≤1.5 x institutional ULN; AST (SGOT), ALT (SGPT) ≤ 2.5 x institutional ULN unless liver metastases are present, in which case ≤5x ULN; INR ≤ 1.25. Albumin ≥ 31 g/dL. Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine clearance CL>40 mL/min by Cockcroft-Gault formula or by 24-hour urine collection
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04522544 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages